Literature DB >> 20226167

Defective calmodulin binding to the cardiac ryanodine receptor plays a key role in CPVT-associated channel dysfunction.

Xiaojuan Xu1, Masafumi Yano, Hitoshi Uchinoumi, Akihiro Hino, Takeshi Suetomi, Makoto Ono, Hiroki Tateishi, Tetsuro Oda, Shinichi Okuda, Masahiro Doi, Shigeki Kobayashi, Takeshi Yamamoto, Yasuhiro Ikeda, Noriaki Ikemoto, Masunori Matsuzaki.   

Abstract

Calmodulin (CaM), one of the accessory proteins of the cardiac ryanodine receptor (RyR2), is known to play a significant role in the channel regulation of the RyR2. However, the possible involvement of calmodulin in the pathogenic process of catecholaminergic polymorphic ventricular tachycardia (CPVT) has not been investigated. In this study, we investigated the state of RyR2-bound CaM and channel dysfunctions using a knock-in (KI) mouse model with CPVT-linked RyR2 mutation (R2474S). Without added effectors, the affinity of CaM binding to the RyR2 was indistinguishable between KI and WT hearts. In response to cAMP (1 micromol/L), the RyR2 phosphorylation at Ser2808 increased in both WT and KI hearts to the same extent. However, cAMP caused a significant decrease of the CaM-binding affinity in KI hearts, but the affinity was unchanged in WT. Dantrolene restored a normal level of CaM-binding affinity in the cAMP-treated KI hearts, suggesting that defective inter-domain interaction between the N-terminal domain and the central domain of the RyR2 (the target of therapeutic effect of dantrolene) is involved in the cAMP-induced reduction of the CaM-binding affinity. In saponin-permeabilized cardiomyocytes, the addition of cAMP increased the frequency of spontaneous Ca(2+) sparks to a significantly larger extent in KI cardiomyocytes than in WT cardiomyocytes, whereas the addition of a high concentration of CaM attenuated the aberrant increase of Ca(2+) sparks. In conclusion, CPVT mutation causes defective inter-domain interaction, significant reduction in the ability of CaM binding to the RyR2, spontaneous Ca(2+) leak, and then lethal arrhythmia. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20226167      PMCID: PMC2858291          DOI: 10.1016/j.bbrc.2010.03.046

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

1.  Peptide probe study of the critical regulatory domain of the cardiac ryanodine receptor.

Authors:  Takeshi Yamamoto; Noriaki Ikemoto
Journal:  Biochem Biophys Res Commun       Date:  2002-03-08       Impact factor: 3.575

Review 2.  Macromolecular complexes regulating cardiac ryanodine receptor function.

Authors:  Donald M Bers
Journal:  J Mol Cell Cardiol       Date:  2004-08       Impact factor: 5.000

Review 3.  Mechanisms of Disease: ryanodine receptor defects in heart failure and fatal arrhythmia.

Authors:  Masafumi Yano; Takeshi Yamamoto; Yasuhiro Ikeda; Masunori Matsuzaki
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2006-01

4.  Localization of a disease-associated mutation site in the three-dimensional structure of the cardiac muscle ryanodine receptor.

Authors:  Zheng Liu; Ruiwu Wang; Jing Zhang; S R Wayne Chen; Terence Wagenknecht
Journal:  J Biol Chem       Date:  2005-09-11       Impact factor: 5.157

5.  Defective regulation of interdomain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure.

Authors:  Tetsuro Oda; Masafumi Yano; Takeshi Yamamoto; Takahiro Tokuhisa; Shinichi Okuda; Masahiro Doi; Tomoko Ohkusa; Yasuhiro Ikeda; Shigeki Kobayashi; Noriaki Ikemoto; Masunori Matsuzaki
Journal:  Circulation       Date:  2005-06-20       Impact factor: 29.690

6.  Apocalmodulin and Ca2+-calmodulin bind to neighboring locations on the ryanodine receptor.

Authors:  Montserrat Samsó; Terence Wagenknecht
Journal:  J Biol Chem       Date:  2001-11-02       Impact factor: 5.157

7.  Molecular basis of calmodulin binding to cardiac muscle Ca(2+) release channel (ryanodine receptor).

Authors:  Naohiro Yamaguchi; Le Xu; Daniel A Pasek; Kelly E Evans; Gerhard Meissner
Journal:  J Biol Chem       Date:  2003-04-21       Impact factor: 5.157

8.  Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology.

Authors:  Y Y Zhou; S Q Wang; W Z Zhu; A Chruscinski; B K Kobilka; B Ziman; S Wang; E G Lakatta; H Cheng; R P Xiao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-07       Impact factor: 4.733

9.  Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death.

Authors:  Dmitry Terentyev; Alessandra Nori; Massimo Santoro; Serge Viatchenko-Karpinski; Zuzana Kubalova; Inna Gyorke; Radmila Terentyeva; Srikanth Vedamoorthyrao; Nico A Blom; Giorgia Valle; Carlo Napolitano; Simon C Williams; Pompeo Volpe; Silvia G Priori; Sandor Gyorke
Journal:  Circ Res       Date:  2006-04-06       Impact factor: 17.367

10.  Blocking the Ca2+-induced conformational transitions in calmodulin with disulfide bonds.

Authors:  R Y Tan; Y Mabuchi; Z Grabarek
Journal:  J Biol Chem       Date:  1996-03-29       Impact factor: 5.157

View more
  36 in total

1.  Dantrolene: from better bacon to a treatment for ventricular fibrillation.

Authors:  Dan M Roden; Björn C Knollmann
Journal:  Circulation       Date:  2014-01-08       Impact factor: 29.690

2.  Divergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants.

Authors:  Hyun Seok Hwang; Florentin R Nitu; Yi Yang; Kafa Walweel; Laetitia Pereira; Christopher N Johnson; Michela Faggioni; Walter J Chazin; Derek Laver; Alfred L George; Razvan L Cornea; Donald M Bers; Björn C Knollmann
Journal:  Circ Res       Date:  2014-02-21       Impact factor: 17.367

3.  Calcium-Dependent Structural Dynamics of a Spin-Labeled RyR Peptide Bound to Calmodulin.

Authors:  Cheng Her; Jesse E McCaffrey; David D Thomas; Christine B Karim
Journal:  Biophys J       Date:  2016-12-06       Impact factor: 4.033

4.  Dantrolene prevents arrhythmogenic Ca2+ release in heart failure.

Authors:  Joshua T Maxwell; Timothy L Domeier; Lothar A Blatter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-16       Impact factor: 4.733

Review 5.  Targeting ryanodine receptors for anti-arrhythmic therapy.

Authors:  Mark D McCauley; Xander H T Wehrens
Journal:  Acta Pharmacol Sin       Date:  2011-06       Impact factor: 6.150

6.  Aberrant interaction of calmodulin with the ryanodine receptor develops hypertrophy in the neonatal cardiomyocyte.

Authors:  Jaya P Gangopadhyay; Noriaki Ikemoto
Journal:  Biochem J       Date:  2011-09-01       Impact factor: 3.857

Review 7.  Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia: risk factor and potential therapeutic target?

Authors:  Michela Faggioni; Christian van der Werf; Bjorn C Knollmann
Journal:  Trends Cardiovasc Med       Date:  2014-07-10       Impact factor: 6.677

8.  In cardiomyocytes, binding of unzipping peptide activates ryanodine receptor 2 and reciprocally inhibits calmodulin binding.

Authors:  Tetsuro Oda; Yi Yang; Florentin R Nitu; Bengt Svensson; Xiyuan Lu; Bradley R Fruen; Razvan L Cornea; Donald M Bers
Journal:  Circ Res       Date:  2012-12-11       Impact factor: 17.367

9.  Nuclear translocation of calmodulin in pathological cardiac hypertrophy originates from ryanodine receptor bound calmodulin.

Authors:  Tetsuro Oda; Takeshi Yamamoto; Takayoshi Kato; Hitoshi Uchinoumi; Go Fukui; Yoriomi Hamada; Takuma Nanno; Hironori Ishiguchi; Yoshihide Nakamura; Yoko Okamoto; Michiaki Kono; Shinichi Okuda; Shigeki Kobayashi; Donald M Bers; Masafumi Yano
Journal:  J Mol Cell Cardiol       Date:  2018-10-22       Impact factor: 5.000

10.  Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death.

Authors:  Mette Nyegaard; Michael T Overgaard; Mads T Søndergaard; Marta Vranas; Elijah R Behr; Lasse L Hildebrandt; Jacob Lund; Paula L Hedley; A John Camm; Göran Wettrell; Inger Fosdal; Michael Christiansen; Anders D Børglum
Journal:  Am J Hum Genet       Date:  2012-10-05       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.